Pfizer
PFE
2,049 hedge funds and large institutions have $141B invested in Pfizer in 2017 Q2 according to their latest regulatory filings, with 83 funds opening new positions, 814 increasing their positions, 911 reducing their positions, and 86 closing their positions.
0.97% less ownership
Funds ownership: 74.86% → 73.89% (-0.97%)
3% less capital invested
Capital invested by funds: $145B → $141B (-$4.15B)
3% less first-time investments, than exits
New positions opened: 83 | Existing positions closed: 86
1% less funds holding
Funds holding: 2,074 → 2,049 (-25)
9% less funds holding in top 10
Funds holding in top 10: 180 → 164 (-16)
11% less repeat investments, than reductions
Existing positions increased: 814 | Existing positions reduced: 911
12% less call options, than puts
Call options by funds: $1.09B | Put options by funds: $1.24B
Top Buyers
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$454M |
| 2 |
Lazard Asset Management
New York
|
-$415M |
| 3 |
CWM
CIBC World Markets
New York
|
-$368M |
| 4 |
MC
Maverick Capital
Dallas,
Texas
|
-$325M |
| 5 |
Bank of New York Mellon
New York
|
-$193M |
PFE Hedge Fund Activity: Q2 2017 in Review
2,049 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q2 2017, worth a combined $141B — down 2.9% from $145B a quarter earlier.
Sellers outnumbered buyers: 86 funds closed out of PFE and 83 opened new positions — a net loss of 3 holders — while 911 trimmed existing stakes and 814 added.
The largest buyer was Janus Henderson Group, adding an estimated $310M. The largest seller was T. Rowe Price Associates, cutting an estimated $454M.
- 2,049 institutional investors held Pfizer (PFE) as of Q2 2017, down from 2,074 in Q1 2017.
- Funds reported $141B of Pfizer stock for Q2 2017, down 2.9% quarter-over-quarter.
- 83 funds opened new Pfizer positions in Q2 2017 and 86 closed out, a net change of -3 holders.
- The largest Pfizer buyer in Q2 2017 was Janus Henderson Group, an estimated $310M added.
- The largest Pfizer seller in Q2 2017 was T. Rowe Price Associates, an estimated $454M sold.
Based on aggregated 13F filings for Q2 2017.